Tetra Bio-Pharma Announces the appointment of Gregory Drohan to its board of directors
OTTAWA, ONTARIO–(Marketwired – April 10, 2018) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018.
The company will nominate Mr. Drohan for election at Tetra’s 2018 Annual Meeting of Shareholders.
Chairman André Rancourt welcomes Mr. Drohan to the board and comments, “We are pleased to welcome Greg as a new Independent director to the Tetra board. His extensive experience as a senior executive and marketer in the consumer products space will bring tremendous vision and skills to the execution and development of the Tetra Bio-Pharma growth strategy.”
“These are exciting times at Tetra and having Greg join us at this pivotal moment in the history of cannabis and its consumption is a tremendous win.” said Guy Chamberland, Interim CEO and CSO of Tetra Bio-Pharma.
“I am excited to be joining the board of Tetra and to be involved with a leading company in an industry that is shaping the future of health care. I can’t wait to put my experience to work alongside Guy and his team of professionals at Tetra,” added Greg Drohan.
Gregory Drohan’s committee appointments will be determined immediately following his election to the board at the 2018 Annual Meeting of Shareholders.
About Gregory Drohan
Until 2013, Greg Drohan was President of the board of Church and Dwight Canada Corp. While with Church and Dwight Canada, Drohan successfully merged the Church & Dwight and Carter-Horner businesses which lead to the doubling of sales revenue and achieved #1 market share on brands such as Trojans, Oxi Clean, First Response, Rub A535 and Arm & Hammer. Following his successful 40-year career in the consumer products sector Mr. Drohan has established a management consulting practice. His previous board experiences include President on the Board of Church and Dwight and director of the Ryerson University Alumni Relations Board. Drohan holds an MBA from York University and a BBM from Ryerson Polytechnical Institute.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
For media information, please contact:
O: 1 514 840 7990
M: 1 514 232 1556